Do new prescription drugs pay for themselves?: The case of second-generation antipsychotics
- 31 January 2005
- journal article
- Published by Elsevier in Journal of Health Economics
- Vol. 24 (1) , 1-31
- https://doi.org/10.1016/j.jhealeco.2004.08.001
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Does contracting out increase the efficiency of government programs? Evidence from Medicaid HMOsJournal of Public Economics, 2004
- The Distortionary Effects of Government Procurement: Evidence from Medicaid Prescription Drug PurchasingPublished by National Bureau of Economic Research ,2004
- Quality-Constant Price Indexes for the Ongoing Treatment of Schizophrenia: An Exploratory StudyPublished by National Bureau of Economic Research ,2003
- Does Medicaid Pay Too Much for Prescription Drugs? A Case Study of Atypical Anti-PsychoticsPublished by National Bureau of Economic Research ,2003
- Differential Effects of Risperidone, Olanzapine, Clozapine, and Conventional Antipsychotics on Type 2 DiabetesThe Journal of Clinical Psychiatry, 2002
- Economic evaluations of novel antipsychotic medications: a literature reviewSchizophrenia Research, 2002
- Effectiveness of Antipsychotic Therapy in a Naturalistic SettingThe Journal of Clinical Psychiatry, 1999
- The Effects of Atypical Antipsychotic Drugs on Neurocognitive Impairment in Schizophrenia: A Review and Meta-analysisSchizophrenia Bulletin, 1999
- The importance of the physician in the generic versus trade-name prescription decision.The RAND Journal of Economics, 1998
- Smearing Estimate: A Nonparametric Retransformation MethodJournal of the American Statistical Association, 1983